vs

Side-by-side financial comparison of Astrana Health, Inc. (ASTH) and Stride, Inc. (LRN). Click either name above to swap in a different company.

Astrana Health, Inc. is the larger business by last-quarter revenue ($950.5M vs $629.9M, roughly 1.5× Stride, Inc.). Stride, Inc. runs the higher net margin — 14.1% vs 0.7%, a 13.4% gap on every dollar of revenue. On growth, Astrana Health, Inc. posted the faster year-over-year revenue change (42.9% vs 2.7%). Over the past eight quarters, Astrana Health, Inc.'s revenue compounded faster (53.3% CAGR vs 6.9%).

Astrana Health, Inc. is a U.S.-based value-based healthcare services provider that primarily serves Medicare-eligible senior populations across the United States. It offers in-home primary care, chronic disease management, and care coordination services, aiming to improve patient health outcomes and reduce unnecessary medical costs.

Stride, Inc. is a for-profit education company that provides online and blended education programs. Stride, Inc. is an education management organization (EMO) that provides online education designed as an alternative to traditional "brick and mortar" education for public school students from kindergarten to 12th grade, as well as career learning programs. As of 2012, publicly traded Stride, Inc. was the largest EMO in terms of enrollment.

ASTH vs LRN — Head-to-Head

Bigger by revenue
ASTH
ASTH
1.5× larger
ASTH
$950.5M
$629.9M
LRN
Growing faster (revenue YoY)
ASTH
ASTH
+40.2% gap
ASTH
42.9%
2.7%
LRN
Higher net margin
LRN
LRN
13.4% more per $
LRN
14.1%
0.7%
ASTH
Faster 2-yr revenue CAGR
ASTH
ASTH
Annualised
ASTH
53.3%
6.9%
LRN

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
ASTH
ASTH
LRN
LRN
Revenue
$950.5M
$629.9M
Net Profit
$6.6M
$88.5M
Gross Margin
Operating Margin
1.9%
20.5%
Net Margin
0.7%
14.1%
Revenue YoY
42.9%
2.7%
Net Profit YoY
184.4%
8.5%
EPS (diluted)
$0.12
$1.93

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASTH
ASTH
LRN
LRN
Q3 26
$629.9M
Q4 25
$950.5M
$631.3M
Q3 25
$956.0M
$620.9M
Q2 25
$654.8M
$653.6M
Q1 25
$620.4M
$613.4M
Q4 24
$665.2M
$587.2M
Q3 24
$478.7M
$551.1M
Q2 24
$486.3M
Net Profit
ASTH
ASTH
LRN
LRN
Q3 26
$88.5M
Q4 25
$6.6M
$99.5M
Q3 25
$373.0K
$68.8M
Q2 25
$9.4M
$51.3M
Q1 25
$6.7M
$99.3M
Q4 24
$-7.8M
$96.4M
Q3 24
$16.1M
$40.9M
Q2 24
$19.2M
Gross Margin
ASTH
ASTH
LRN
LRN
Q3 26
Q4 25
41.1%
Q3 25
39.0%
Q2 25
36.6%
Q1 25
40.6%
Q4 24
40.8%
Q3 24
39.2%
Q2 24
Operating Margin
ASTH
ASTH
LRN
LRN
Q3 26
20.5%
Q4 25
1.9%
23.3%
Q3 25
2.0%
11.1%
Q2 25
3.1%
8.7%
Q1 25
3.3%
21.3%
Q4 24
0.1%
21.3%
Q3 24
5.9%
8.6%
Q2 24
6.2%
Net Margin
ASTH
ASTH
LRN
LRN
Q3 26
14.1%
Q4 25
0.7%
15.8%
Q3 25
0.0%
11.1%
Q2 25
1.4%
7.9%
Q1 25
1.1%
16.2%
Q4 24
-1.2%
16.4%
Q3 24
3.4%
7.4%
Q2 24
3.9%
EPS (diluted)
ASTH
ASTH
LRN
LRN
Q3 26
$1.93
Q4 25
$0.12
$2.12
Q3 25
$0.01
$1.40
Q2 25
$0.19
$0.96
Q1 25
$0.14
$2.02
Q4 24
$-0.14
$2.03
Q3 24
$0.33
$0.94
Q2 24
$0.40

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASTH
ASTH
LRN
LRN
Cash + ST InvestmentsLiquidity on hand
$429.5M
$614.0M
Total DebtLower is stronger
$417.6M
Stockholders' EquityBook value
$779.3M
$1.6B
Total Assets
$2.2B
$2.4B
Debt / EquityLower = less leverage
0.25×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASTH
ASTH
LRN
LRN
Q3 26
$614.0M
Q4 25
$429.5M
$625.7M
Q3 25
$463.4M
$715.1M
Q2 25
$342.1M
$985.3M
Q1 25
$260.9M
$723.7M
Q4 24
$290.8M
$717.5M
Q3 24
$350.3M
$522.2M
Q2 24
$327.7M
Total Debt
ASTH
ASTH
LRN
LRN
Q3 26
$417.6M
Q4 25
$417.2M
Q3 25
$416.8M
Q2 25
$416.3M
Q1 25
$415.9M
Q4 24
$415.5M
Q3 24
$415.1M
Q2 24
Stockholders' Equity
ASTH
ASTH
LRN
LRN
Q3 26
$1.6B
Q4 25
$779.3M
$1.5B
Q3 25
$775.5M
$1.5B
Q2 25
$765.5M
$1.5B
Q1 25
$745.4M
$1.4B
Q4 24
$712.7M
$1.3B
Q3 24
$704.6M
$1.2B
Q2 24
$678.9M
Total Assets
ASTH
ASTH
LRN
LRN
Q3 26
$2.4B
Q4 25
$2.2B
$2.3B
Q3 25
$2.2B
$2.3B
Q2 25
$1.4B
$2.3B
Q1 25
$1.3B
$2.2B
Q4 24
$1.4B
$2.1B
Q3 24
$1.3B
$2.0B
Q2 24
$1.3B
Debt / Equity
ASTH
ASTH
LRN
LRN
Q3 26
0.25×
Q4 25
0.27×
Q3 25
0.27×
Q2 25
0.28×
Q1 25
0.29×
Q4 24
0.32×
Q3 24
0.34×
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASTH
ASTH
LRN
LRN
Operating Cash FlowLast quarter
$-2.9M
$117.0M
Free Cash FlowOCF − Capex
$-6.0M
FCF MarginFCF / Revenue
-0.6%
Capex IntensityCapex / Revenue
0.3%
Cash ConversionOCF / Net Profit
-0.44×
1.32×
TTM Free Cash FlowTrailing 4 quarters
$104.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASTH
ASTH
LRN
LRN
Q3 26
$117.0M
Q4 25
$-2.9M
$91.8M
Q3 25
$10.0M
$-195.8M
Q2 25
$90.9M
$298.3M
Q1 25
$16.6M
$53.1M
Q4 24
$-10.9M
$223.4M
Q3 24
$34.0M
$-142.0M
Q2 24
$23.2M
Free Cash Flow
ASTH
ASTH
LRN
LRN
Q3 26
Q4 25
$-6.0M
$91.6M
Q3 25
$7.4M
$-196.1M
Q2 25
$89.5M
$297.9M
Q1 25
$13.6M
$52.9M
Q4 24
$-13.5M
$222.9M
Q3 24
$31.7M
$-142.7M
Q2 24
$20.4M
FCF Margin
ASTH
ASTH
LRN
LRN
Q3 26
Q4 25
-0.6%
14.5%
Q3 25
0.8%
-31.6%
Q2 25
13.7%
45.6%
Q1 25
2.2%
8.6%
Q4 24
-2.0%
38.0%
Q3 24
6.6%
-25.9%
Q2 24
4.2%
Capex Intensity
ASTH
ASTH
LRN
LRN
Q3 26
Q4 25
0.3%
0.0%
Q3 25
0.3%
0.0%
Q2 25
0.2%
0.1%
Q1 25
0.5%
0.0%
Q4 24
0.4%
0.1%
Q3 24
0.5%
0.1%
Q2 24
0.6%
Cash Conversion
ASTH
ASTH
LRN
LRN
Q3 26
1.32×
Q4 25
-0.44×
0.92×
Q3 25
26.69×
-2.85×
Q2 25
9.65×
5.81×
Q1 25
2.48×
0.53×
Q4 24
2.32×
Q3 24
2.11×
-3.47×
Q2 24
1.21×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASTH
ASTH

Medicare$542.4M57%
Commercial$99.1M10%
Care Delivery$92.1M10%
Care Enablement$78.9M8%
Other Third Parties$58.0M6%
Health Care Patient Service$39.8M4%
Health Care Other$25.5M3%
Other$12.1M1%
Management Service$10.3M1%

LRN
LRN

General Education$357.5M57%
Middle - High School$259.5M41%
Adult$12.9M2%

Related Comparisons